A new automated multiple allergen simultaneous test-chemiluminescent assay (MAST-CLA) using an AP720S analyzer

Lee, Sungsil; Lim, Hwan Sub; Park, Jungyong; Kim, Hyun Sook

doi:10.1016/j.cca.2009.01.014

Cited by 21 publications

(14 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, allergen-speci�c IgE assays are o�en modi�ed as manufacturers improve allergens or change reagents to optimize test performance, affecting the diagnostic performance of those assays. MAST Optigen (Hitachi Chemical Diagnostics, Mountain View, CA, USA), upgraded version of MAST CLA (Hitachi Chemical Diagnostics, Mountain View, CA, USA), and Polycheck Allergy (Biocheck GmbH, Munster, Germany) were recently introduced with good performances [6,9,10]. However, to the best of our knowledge, comparison of performances of those assays and analysis of concordance with ImmunoCAP system has not been performed.…”

Section: Introductionmentioning

confidence: 99%

Comparison of Multiple Allergen Simultaneous Test and ImmunoCAP for the Diagnosis of Allergic Rhinitis

Do-Youn¹,

Park²,

Hong³

et al. 2018

Korean J Otorhinolaryngol-Head Neck Surg

View full text Add to dashboard Cite

). Forty sera that tested positive with the RIDA Allergy Screen (20 for food and 20 for inhalant panel) were subjected to MAST Optigen and Polycheck Allergy. For 26 available sera with discrepant results, 62 ImmunoCAP allergen-speci�c IgE tests (Pharmacia Diagnostics, Uppsala, Sweden) were performed. Percent agreements (kappa value) were 87.6% (0.59) and 91.3% (0.60) between RIDA and MAST; 89.9% (0.55) and 88.3% (0.46) between RIDA and Polycheck; and 86.8% (0.51) and 90.6% (0.61) between MAST and Polycheck. Compared with ImmunoCAP, agreements (kappa value) of inhalant and food panels were 51.7% (0.04) and 33.3% (−0.38) for RIDA; 60.7% (0.27) and 81.8% (0.59) for MAST; and 65.5% (0.26) and 45.5% (0.07) for Polycheck. e agreements between RIDA, MAST, and Polycheck and ImmunoCAP-positivity were 45.7%, 88.2%, and 28.6%, respectively, and the agreements for ImmunoCAP-negativity were 37.0%, 51.9%, and 88.9%. MAST Optigen showed better agreement with ImmunoCAP than other assays in the food panel. Better sensitivity of MAST Optigen and better speci�city of Polycheck Allergy were suspected.

show abstract

Section: Introductionmentioning

confidence: 99%

Comparison of Multiple Allergen Simultaneous Test and ImmunoCAP for the Diagnosis of Allergic Rhinitis

Do-Youn¹,

Park²,

Hong³

et al. 2018

Korean J Otorhinolaryngol-Head Neck Surg

View full text Add to dashboard Cite

show abstract

“…Although in vivo skin test has been traditionally used in the clinical environments, there are several limitations of in vivo skin test including error-prone results in patients with anti-histamine medication or skin diseases such as dermographism, possibility of subjective interpretation, and the lack of standardization for protocols [3] , [4] . Therefore, in vitro allergen-specific IgE measurements have been developed using various principles of radioimmunoassay, enzyme immunoassay, fluorescent enzyme immunoassay, immunoblot, and chemiluminescent assay [5] , [6] , [7] .…”

Section: Introductionmentioning

confidence: 99%

“…Among the commercially available in vitro allergy tests, multiple allergen simultaneous tests (MAST) have been continuously developed with the improvements in smaller amounts of serum consumption, shorter turnaround time, and wider spectrum of allergens included in the test [6] , [8] , [9] , [10] , [11] , [12] . Since the difference in prevalence of allergic diseases according to age, sex, and ethnicity is prominent, the selection of multiple allergen screening panels should be modified in the context of geographical regions and race of the target populations [13] , [14] , [15] .…”

Section: Introductionmentioning

confidence: 99%

Comparison and clinical utility evaluation of four multiple allergen simultaneous tests including two newly introduced fully automated analyzers

Rim

Park

Kim

et al. 2016

Practical Laboratory Medicine

View full text Add to dashboard Cite

BackgroundWe compared the diagnostic performances of two newly introduced fully automated multiple allergen simultaneous tests (MAST) analyzers with two conventional MAST assays.MethodsThe serum samples from a total of 53 and 104 patients were tested for food panels and inhalant panels, respectively, in four analyzers including AdvanSure AlloScreen (LG Life Science, Korea), AdvanSure Allostation Smart II (LG Life Science), PROTIA Allergy-Q (ProteomeTech, Korea), and RIDA Allergy Screen (R-Biopharm, Germany). We compared not only the total agreement percentages but also positive propensities among four analyzers.ResultsEvaluation of AdvanSure Allostation Smart II as upgraded version of AdvanSure AlloScreen revealed good concordance with total agreement percentages of 93.0% and 92.2% in food and inhalant panel, respectively. Comparisons of AdvanSure Allostation Smart II or PROTIA Allergy-Q with RIDA Allergy Screen also showed good concordance performance with positive propensities of two new analyzers for common allergens (Dermatophagoides farina and Dermatophagoides pteronyssinus). The changes of cut-off level resulted in various total agreement percentage fluctuations among allergens by different analyzers, although current cut-off level of class 2 appeared to be generally suitable.ConclusionsAdvanSure Allostation Smart II and PROTIA Allergy-Q presented favorable agreement performances with RIDA Allergy Screen, although positive propensities were noticed in common allergens.

show abstract

“…However, allergen-specific IgE assays are often modified as manufacturers improve allergens or change reagents to optimize test performance, affecting the diagnostic performance of those assays. MAST Optigen (Hitachi Chemical Diagnostics, Mountain View, CA, USA), upgraded version of MAST CLA (Hitachi Chemical Diagnostics, Mountain View, CA, USA), and Polycheck Allergy (Biocheck GmbH, Munster, Germany) were recently introduced with good performances [6, 9, 10]. However, to the best of our knowledge, comparison of performances of those assays and analysis of concordance with ImmunoCAP system has not been performed.…”

Section: Introductionmentioning

confidence: 99%

Comparison of Three Multiple Allergen Simultaneous Tests: RIDA Allergy Screen, MAST Optigen, and Polycheck Allergy

Han

Shin

Park

et al. 2013

BioMed Research International

View full text Add to dashboard Cite

We compared the performances of 3 Multiple Allergen Simultaneous Test (MAST) assays: RIDA Allergy Screen (R-Biopharm, Darmstadt, Germany), MAST Optigen allergy system (Hitachi Chemical Diagnostics, Mountain View, CA), and Polycheck Allergy (Biocheck GmbH, Munster, Germany). Forty sera that tested positive with the RIDA Allergy Screen (20 for food and 20 for inhalant panel) were subjected to MAST Optigen and Polycheck Allergy. For 26 available sera with discrepant results, 62 ImmunoCAP allergen-specific IgE tests (Pharmacia Diagnostics, Uppsala, Sweden) were performed. Percent agreements (kappa value) were 87.6% (0.59) and 91.3% (0.60) between RIDA and MAST; 89.9% (0.55) and 88.3% (0.46) between RIDA and Polycheck; and 86.8% (0.51) and 90.6% (0.61) between MAST and Polycheck. Compared with ImmunoCAP, agreements (kappa value) of inhalant and food panels were 51.7% (0.04) and 33.3% (−0.38) for RIDA; 60.7% (0.27) and 81.8% (0.59) for MAST; and 65.5% (0.26) and 45.5% (0.07) for Polycheck. The agreements between RIDA, MAST, and Polycheck and ImmunoCAP-positivity were 45.7%, 88.2%, and 28.6%, respectively, and the agreements for ImmunoCAP-negativity were 37.0%, 51.9%, and 88.9%. MAST Optigen showed better agreement with ImmunoCAP than other assays in the food panel. Better sensitivity of MAST Optigen and better specificity of Polycheck Allergy were suspected.

show abstract

A new automated multiple allergen simultaneous test-chemiluminescent assay (MAST-CLA) using an AP720S analyzer

Cited by 21 publications

References 9 publications

Comparison of Multiple Allergen Simultaneous Test and ImmunoCAP for the Diagnosis of Allergic Rhinitis

Comparison of Multiple Allergen Simultaneous Test and ImmunoCAP for the Diagnosis of Allergic Rhinitis

Comparison and clinical utility evaluation of four multiple allergen simultaneous tests including two newly introduced fully automated analyzers

Comparison of Three Multiple Allergen Simultaneous Tests: RIDA Allergy Screen, MAST Optigen, and Polycheck Allergy

Contact Info

Product

Resources

About